At the news
? BEARISHIMPACT 7/10 8-K filed Sep 9, 2026 at 21:45 ET
Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338,974 shares, priced at Nasdaq Minimum Price plus $0.015. This capital raise follows a recently filed $100M ATM offering and an S-3 resale registration, creating a dual-track dilution scenario for a company with no active clinical programs and a going-concern risk. The massive dilution (15.3% of outstanding shares from this placement alone, plus the ATM overhang) is the dominant signal, overwhelming any positive from the cash infusion.
- Indaptus entered a $24M private placement of 20,338,974 shares at Nasdaq Minimum Price + $0.015.
- The company has 133,242,324 shares outstanding; this placement represents ~15.3% dilution.
- Proceeds are for working capital, R&D, and early-stage research on a neurotechnology device for sleep conditions.
- This filing follows a $100M ATM offering (filed Aug 31, 2026) and an S-3 resale registration for 58.9M shares (filed Aug 17, 2026).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access